|
US2019183907A1
|
|
Compositions comprising dexamethasone
|
|
US2019125676A1
|
|
Compositions comprising proton pump inhibitors for oral administration
|
|
WO2018047163A1
|
|
Ophthalmic compositions
|
|
AU2017406466A1
|
|
Compositions comprising biodegradable copolymers
|
|
WO2017145146A1
|
|
Compositions comprising proton pump inhibitors
|
|
WO2017125912A1
|
|
Methods for treating helicobacter infection
|
|
US2017360697A1
|
|
Stable orally disintegrating pharmaceutical compositions
|
|
WO2017017679A1
|
|
Compositions comprising atorvastatin or a pharmaceutically acceptable salt thereof
|
|
US2017042806A1
|
|
Orally disintegrating compositions
|
|
AU2015365566A1
|
|
Alternating and semi-alternating poly(ester-anhydride) copolymers
|
|
WO2015198304A1
|
|
Pharmaceutical compositions comprising ferric citrate and methods for the production thereof
|
|
AU2012238327A1
|
|
Stable atorvastatin formulations
|
|
IL216966D0
|
|
Local therapeutic release device
|
|
IL215782D0
|
|
Solid biodegradable oral delivery device for use in treating a periodontal disease
|
|
WO2011111027A2
|
|
Oral dispersible delayed release tablet formulation
|
|
EP2366378A1
|
|
Sustained-release donepezil formulations
|
|
IL210279D0
|
|
Extended release compositions for high solubility, high permeability acdtive pharmaceutical ingredients
|
|
IL209631D0
|
|
Process for manufacture of a medicament with granulation and pan coating
|
|
IL208925D0
|
|
Stable benzimidazole formulation
|
|
IL207725D0
|
|
Humidity-resistant drug formulations and methods of preparation thereof
|
